Cheap-to-Truth Radarhttps://machineoverhuman.com/cheap-to-truth/radarDaily source-backed drug-development signals generated by GrowthForge.en-usThu, 08 Oct 2026 11:15:03 GMTNCT00319228: Safety, Pharmacokinetics and Efficacy of an ATIII Concentratehttps://machineoverhuman.com/cheap-to-truth/radar/nct00319228https://machineoverhuman.com/cheap-to-truth/radar/nct00319228Wed, 07 Oct 2026 12:00:00 GMTTERMINATED · Plasma-derived AT-III concentrate · priority to inspect 82/100NCT05421013: Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCChttps://machineoverhuman.com/cheap-to-truth/radar/nct05421013https://machineoverhuman.com/cheap-to-truth/radar/nct05421013Wed, 07 Oct 2026 12:00:00 GMTTERMINATED · STP705 · priority to inspect 82/100NCT00893516: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphomahttps://machineoverhuman.com/cheap-to-truth/radar/nct00893516https://machineoverhuman.com/cheap-to-truth/radar/nct00893516Wed, 07 Oct 2026 12:00:00 GMTTERMINATED · CHOP + CD4, CHOP · priority to inspect 82/100NCT01329809: Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resectionhttps://machineoverhuman.com/cheap-to-truth/radar/nct01329809https://machineoverhuman.com/cheap-to-truth/radar/nct01329809Fri, 02 Oct 2026 12:00:00 GMTTERMINATED · Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) · priority to inspect 82/100NCT05359861: Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinomahttps://machineoverhuman.com/cheap-to-truth/radar/nct05359861https://machineoverhuman.com/cheap-to-truth/radar/nct05359861Thu, 01 Oct 2026 12:00:00 GMTTERMINATED · Casdozokitug, Atezolizumab, Bevacizumab, Placebo · priority to inspect 82/100NCT06984328: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)https://machineoverhuman.com/cheap-to-truth/radar/nct06984328https://machineoverhuman.com/cheap-to-truth/radar/nct06984328Wed, 30 Sep 2026 12:00:00 GMTTERMINATED · Acasunlimab, Pembrolizumab · priority to inspect 82/100NCT03896945: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophreniahttps://machineoverhuman.com/cheap-to-truth/radar/nct03896945https://machineoverhuman.com/cheap-to-truth/radar/nct03896945Tue, 29 Sep 2026 12:00:00 GMTTERMINATED · Placebo, AVP-786 · priority to inspect 82/100NCT06055075: A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myelomahttps://machineoverhuman.com/cheap-to-truth/radar/nct06055075https://machineoverhuman.com/cheap-to-truth/radar/nct06055075Tue, 29 Sep 2026 12:00:00 GMTTERMINATED · Forimtamig, Carfilzomib, Daratumumab · priority to inspect 82/100NCT04717375: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumorshttps://machineoverhuman.com/cheap-to-truth/radar/nct04717375https://machineoverhuman.com/cheap-to-truth/radar/nct04717375Tue, 29 Sep 2026 12:00:00 GMTTERMINATED · SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed · priority to inspect 82/100NCT07052513: Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgeryhttps://machineoverhuman.com/cheap-to-truth/radar/nct07052513https://machineoverhuman.com/cheap-to-truth/radar/nct07052513Mon, 21 Sep 2026 12:00:00 GMTSUSPENDED · Placebo, M2RLAB 001 · priority to inspect 80/100NCT06039202: CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancerhttps://machineoverhuman.com/cheap-to-truth/radar/nct06039202https://machineoverhuman.com/cheap-to-truth/radar/nct06039202Fri, 18 Sep 2026 12:00:00 GMTSUSPENDED · CA102N, TAS-102, Bevacizumab · priority to inspect 80/100NCT02354014: Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBhttps://machineoverhuman.com/cheap-to-truth/radar/nct02354014https://machineoverhuman.com/cheap-to-truth/radar/nct02354014Thu, 17 Sep 2026 12:00:00 GMTSUSPENDED · Bedaquiline (TMC207), Background Regimen (BR) · priority to inspect 80/100